Karyopharm’s Xpovio In Multiple Myeloma Priced At $22,000 Per Four-Week Cycle
Immediate interaction with US FDA after stressful advisory committee facilitated accelerated approval in fourth-line myeloma, company says. Four different dosing regimens will be priced at $22,000 for four weeks.
You may also be interested in...
More Phase III trials announced from Alexion and Novartis, while Karyopharm investigates potential of repurposed cancer therapy.
The anti-CD38 antibody will face an entrenched rival, J&J's Darzalex, for multiple myeloma.
The European Commission has approved Johnson & Johnson’s/Genmab’s CD38-targeted MAb, daratumumab, and Merck & Co’s checkpoint inhibitor, pembrolizumab, in two first-line additional indications, in multiple myeloma and head and neck cancer, respectively.